MeSH term
Frequency | Condition_Probility | Adult | 19 | 0.0 |
Aged | 16 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 10 | 2.0 |
Cisplatin/administration & dosage | 8 | 3.0 |
*DNA-Binding Proteins | 48 | 2.0 |
Deoxycytidine/administration & dosage/*analogs & derivatives | 3 | 15.0 |
*Endonucleases | 75 | 78.0 |
Female | 56 | 0.0 |
Humans | 154 | 0.0 |
Male | 36 | 0.0 |
Middle Aged | 22 | 0.0 |
Prospective Studies | 2 | 0.0 |
Proteins/*genetics/metabolism | 4 | 1.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
Research Support, Non-U.S. Gov't | 109 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 64 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 18 | 0.0 |
Survival Rate | 7 | 0.0 |
Treatment Outcome | 8 | 0.0 |
Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Biotransformation | 2 | 0.0 |
Cell Hypoxia/physiology | 2 | 2.0 |
Cell Line | 22 | 0.0 |
DNA Repair/*physiology | 4 | 3.0 |
Gamma Rays | 3 | 1.0 |
Radiation Tolerance/genetics/*physiology | 2 | 28.0 |
Cells, Cultured | 12 | 0.0 |
Comparative Study | 23 | 0.0 |
*DNA Repair | 47 | 6.0 |
Kinetics | 6 | 0.0 |
Models, Biological | 2 | 0.0 |
Pyrimidine Dimers/metabolism | 2 | 11.0 |
Ultraviolet Rays | 16 | 2.0 |
Aged, 80 and over | 5 | 0.0 |
Case-Control Studies | 5 | 0.0 |
DNA Helicases/*genetics/metabolism | 2 | 14.0 |
DNA Repair/genetics | 6 | 3.0 |
DNA-Binding Proteins/*genetics/metabolism | 4 | 0.0 |
*Drosophila Proteins | 4 | 0.0 |
Gene Expression | 14 | 0.0 |
Risk Factors | 4 | 0.0 |
Binding Sites | 11 | 0.0 |
DNA/metabolism | 5 | 0.0 |
Endonucleases/*genetics | 7 | 46.0 |
*Gene Deletion | 2 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Base Sequence | 20 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 2 | 1.0 |
Hela Cells | 10 | 0.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 23 | 0.0 |
Tumor Cells, Cultured | 19 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 4 | 0.0 |
Exons | 4 | 0.0 |
Molecular Sequence Data | 30 | 0.0 |
Ovarian Neoplasms/*genetics/pathology | 2 | 2.0 |
Animals | 59 | 0.0 |
Chromosome Mapping | 9 | 0.0 |
Chromosomes, Human, Pair 19 | 2 | 1.0 |
*Genome | 2 | 1.0 |
*Genome, Human | 2 | 0.0 |
Mice | 22 | 0.0 |
Proteins/*genetics | 18 | 1.0 |
Sequence Alignment | 3 | 0.0 |
DNA Damage | 20 | 2.0 |
Endonucleases/*metabolism | 3 | 15.0 |
In Vitro | 2 | 0.0 |
Blotting, Western | 7 | 0.0 |
DNA Repair | 22 | 3.0 |
DNA-Binding Proteins/metabolism | 5 | 0.0 |
Dose-Response Relationship, Radiation | 10 | 2.0 |
Endonucleases/metabolism | 4 | 16.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Up-Regulation | 3 | 0.0 |
DNA Primers | 6 | 0.0 |
Fluorouracil/administration & dosage | 3 | 2.0 |
Organoplatinum Compounds/administration & dosage | 2 | 18.0 |
Prognosis | 6 | 0.0 |
Proteins/*metabolism | 7 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Survival Analysis | 6 | 0.0 |
CHO Cells | 16 | 0.0 |
Cell Survival/drug effects | 5 | 0.0 |
Hamsters | 30 | 0.0 |
Models, Molecular | 2 | 0.0 |
Blotting, Northern | 6 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
DNA Repair/*genetics | 33 | 10.0 |
Genotype | 10 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Time Factors | 7 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Gene Library | 4 | 0.0 |
Gene Targeting | 2 | 0.0 |
Immunoblotting | 4 | 0.0 |
*Recombination, Genetic | 7 | 2.0 |
*DNA Damage | 11 | 1.0 |
DNA-Binding Proteins/*genetics | 11 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Antineoplastic Agents/pharmacology | 4 | 0.0 |
Carboplatin/administration & dosage | 2 | 4.0 |
Clinical Trials | 4 | 0.0 |
Drug Resistance, Neoplasm | 8 | 1.0 |
Cell Division/drug effects/radiation effects | 2 | 8.0 |
Mitomycin/pharmacology | 5 | 5.0 |
Phenotype | 6 | 0.0 |
*Ultraviolet Rays | 5 | 2.0 |
X-Rays | 2 | 1.0 |
Apoptosis | 2 | 0.0 |
DNA Adducts | 3 | 4.0 |
Drug Synergism | 3 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 2 | 1.0 |
Adolescent | 6 | 0.0 |
*Questionnaires | 2 | 5.0 |
Cell Survival/radiation effects | 3 | 3.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Cisplatin/*pharmacology | 8 | 6.0 |
DNA-Binding Proteins/genetics/physiology | 2 | 2.0 |
Down-Regulation | 5 | 0.0 |
Mutation | 14 | 0.0 |
Proteins/genetics/physiology | 3 | 4.0 |
Cell Line, Tumor | 4 | 0.0 |
Cell Survival/*drug effects | 3 | 3.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Xeroderma Pigmentosum/genetics/pathology | 2 | 100.0 |
Antineoplastic Agents/*toxicity | 2 | 3.0 |
Base Pair Mismatch | 3 | 1.0 |
Cisplatin/*toxicity | 2 | 9.0 |
DNA Repair/drug effects/*genetics | 2 | 22.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Proteins/genetics | 12 | 1.0 |
Alleles | 4 | 0.0 |
Antineoplastic Agents/*therapeutic use | 7 | 1.0 |
Polymorphism, Genetic | 9 | 0.0 |
Antineoplastic Agents/*pharmacology | 7 | 0.0 |
DNA, Recombinant | 2 | 1.0 |
Transfection | 14 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism/radiation effects | 2 | 18.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Dimerization | 2 | 0.0 |
Escherichia coli | 3 | 0.0 |
Genetic Complementation Test | 12 | 2.0 |
Precipitin Tests | 6 | 0.0 |
Protein Binding | 10 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics/pathology | 2 | 66.0 |
Lung Neoplasms/*drug therapy/*genetics/pathology | 2 | 66.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Cell-Free System | 4 | 1.0 |
Drug Resistance, Neoplasm/*physiology | 2 | 6.0 |
Ovarian Neoplasms/*genetics/metabolism | 2 | 5.0 |
Platinum/pharmacology | 2 | 100.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
Heterozygote | 3 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Protein Biosynthesis | 7 | 0.0 |
Blotting, Southern | 11 | 0.0 |
Gene Deletion | 4 | 0.0 |
Proteins/genetics/*metabolism | 7 | 1.0 |
Recombination, Genetic/*genetics | 3 | 4.0 |
Adenine Phosphoribosyltransferase/genetics | 3 | 33.0 |
Substrate Specificity | 4 | 0.0 |
Gene Frequency | 2 | 0.0 |
Odds Ratio | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Autoradiography | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Cisplatin/pharmacology | 7 | 4.0 |
DNA Repair/physiology | 2 | 5.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 2 | 2.0 |
DNA-Binding Proteins/genetics/*metabolism | 5 | 0.0 |
Endonucleases/genetics/*metabolism | 3 | 30.0 |
Binding Sites/genetics | 2 | 0.0 |
Ovarian Neoplasms/drug therapy/*genetics | 4 | 57.0 |
DNA Replication | 3 | 0.0 |
Polyploidy | 2 | 5.0 |
Proteins/genetics/*physiology | 2 | 1.0 |
DNA/drug effects/metabolism | 2 | 4.0 |
DNA Repair/drug effects/genetics | 2 | 100.0 |
Comet Assay | 2 | 2.0 |
*DNA Helicases | 13 | 6.0 |
Exons/genetics | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
*Transcription Factors | 14 | 0.0 |
DNA Damage/drug effects | 2 | 4.0 |
Drug Resistance, Neoplasm/genetics | 7 | 10.0 |
Cisplatin/metabolism/*pharmacology | 2 | 40.0 |
RNA, Messenger/analysis | 5 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Endonucleases/genetics | 2 | 20.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Thymidylate Synthase/genetics | 2 | 15.0 |
DNA/analysis | 3 | 0.0 |
DNA Repair/*drug effects | 2 | 6.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Xeroderma Pigmentosum | 2 | 13.0 |
DNA/*metabolism | 2 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Recombination, Genetic | 5 | 0.0 |
Amino Acid Sequence | 15 | 0.0 |
Cell Cycle | 3 | 0.0 |
Cell Survival | 4 | 0.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Sequence Deletion | 5 | 0.0 |
DNA-Binding Proteins/*chemistry/metabolism | 3 | 4.0 |
Biopsy | 2 | 0.0 |
DNA-Binding Proteins/*biosynthesis | 2 | 1.0 |
Endonucleases/*biosynthesis | 2 | 66.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Mitomycin/*pharmacology | 2 | 8.0 |
DNA Adducts/*metabolism | 3 | 6.0 |
Proteins/analysis/genetics | 2 | 9.0 |
DNA, Neoplasm/analysis/genetics | 2 | 2.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Cisplatin/therapeutic use | 4 | 10.0 |
*Mutation | 5 | 0.0 |
Child | 3 | 0.0 |
Child, Preschool | 2 | 0.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Fungal Proteins/metabolism | 4 | 2.0 |
Macromolecular Substances | 3 | 0.0 |
*Saccharomyces cerevisiae Proteins | 5 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Proteins/*physiology | 2 | 1.0 |
DNA Mutational Analysis | 3 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Cisplatin/*therapeutic use | 4 | 12.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Mutagens/*toxicity | 2 | 1.0 |
Proteins/*analysis/genetics | 2 | 8.0 |
*Chromosomes | 2 | 3.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Carboplatin/therapeutic use | 2 | 22.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
*Chromosomes, Human, Pair 19 | 16 | 5.0 |
Genetic Markers | 6 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 6 | 0.0 |
Mutagens/pharmacology | 3 | 7.0 |
*DNA Glycosylases | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase | 2 | 1.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Antibodies | 2 | 0.0 |
Proteins/chemistry/*metabolism | 2 | 2.0 |
DNA-Binding Proteins/*metabolism | 6 | 0.0 |
Distamycins/pharmacology | 2 | 18.0 |
Melphalan/pharmacology | 3 | 18.0 |
Nitrogen Mustard Compounds/pharmacology | 2 | 22.0 |
Cosmids | 5 | 1.0 |
Restriction Mapping | 5 | 0.0 |
Molecular Weight | 3 | 0.0 |
Radiation Tolerance | 2 | 2.0 |
Mutagenesis | 2 | 0.0 |
*Cell Hypoxia | 2 | 2.0 |
Antibody Specificity | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Cricetulus | 2 | 0.0 |
DNA Probes | 5 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Brain/*metabolism | 2 | 0.0 |
Brain Neoplasms/*metabolism | 2 | 2.0 |
*Chromosome Mapping | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Karyotyping | 2 | 0.0 |
Lung Neoplasms/*drug therapy/*genetics | 2 | 33.0 |
Drug Resistance/genetics | 3 | 1.0 |
*Protein Biosynthesis | 3 | 0.0 |
Saccharomyces cerevisiae/metabolism | 3 | 2.0 |
Xeroderma Pigmentosum/*genetics | 2 | 3.0 |
Saccharomyces cerevisiae/*genetics | 2 | 1.0 |
*Genetic Markers | 3 | 0.0 |
Hybrid Cells | 5 | 0.0 |
Ribonucleotide Reductases/genetics | 2 | 40.0 |
Chromosome Banding | 2 | 0.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
Pedigree | 3 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Myotonic Dystrophy/*genetics | 3 | 4.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Creatine Kinase/*genetics | 2 | 10.0 |
*Genes | 2 | 0.0 |
Hybrid Cells/radiation effects | 2 | 4.0 |
Proteins/metabolism | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics | 2 | 66.0 |
